Abstract
Methods Plasma metabolic profiles in 26 PC patients, 27 DM patients, and 23 healthy volunteers were examined using an ultraperformance liquid chromatography coupled with tandem mass spectrometry platform. Differential metabolite ions were then identified using the principal component analysis (PCA) model and the orthogonal partial least-squares discrimination analysis (OPLS-DA) model. The diagnosis performance of metabolite biomarkers was validated by logistic regression models. Results We established a PCA model (R2X = 23.5%, Q2 = 8.21%) and an OPLS-DA model (R2X = 70.0%, R2Y = 84.9%, Q2 = 69.7%). LysoPC (16 : 0), catelaidic acid, cerebronic acid, nonadecanetriol, and asparaginyl-histidine were found to identify PC, with a sensitivity of 89% and a specificity of 91%. Besides, lysoPC (16 : 0), lysoPC (16 : 1), lysoPC (22 : 6), and lysoPC (20 : 3) were found to differentiate PC from DM, with higher accuracy (68% versus 55%) and higher AUC values (72% versus 63%) than those of CA19-9. The diagnostic performance of metabolite biomarkers was finally validated by logistic regression models. Conclusion We succeeded in screening differential metabolite ions among PC and DM patients and healthy individuals, thus providing a preliminary basis for screening the biomarkers for the early diagnosis of PC.
Highlights
Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor characterized by rapid progression and early metastasis, which results in an incurability rate of 96% and a recurrence rate of 80% after diagnosis [1, 2]
Differences in plasma metabolic profiles among PC patients, diabetes mellitus (DM) patients, and healthy volunteers were identified by the principal component analysis (PCA) analysis
Diagnosis is promising for improving the survival rates and prognosis of PC patients
Summary
Pancreatic cancer (PC) is a highly malignant gastrointestinal tumor characterized by rapid progression and early metastasis, which results in an incurability rate of 96% and a recurrence rate of 80% after diagnosis [1, 2]. More than 80% of PC patients at the time of diagnosis already have had an unresectable, locally advanced, and metastatic tumor [5]. Diagnosis has been accepted to hold promise for improving the prognosis of PC. Carbohydrate antigen 19-9 (CA19-9) based approaches differentiate less than 60% of cases of pancreatic cancer (PC) from those of pancreatic tissue damage caused by chronic pancreatitis and type 2 diabetes mellitus (DM). Is study aims to identify potential blood-derived candidate biomarkers for improved diagnosis sensitivity. Differential metabolite ions were identified using the principal component analysis (PCA) model and the orthogonal partial least-squares discrimination analysis (OPLS-DA) model
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
